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Abstract Electrolyte and acid–base abnormalities are a
frequent and potentially dangerous complication in sub-
jects with congestive heart failure. This may be due either
to the pathophysiological alterations present in the heart
failure state leading to neurohumoral activation (stimula-
tion of the renin–angiotensin–aldosterone system, sympa-
thoadrenergic stimulation), or to the adverse events of
therapy with diuretics, cardiac glycosides, and ACE in-
hibitors. Subjects with heart failure may show hypona-
tremia, magnesium, and potassium deficiencies; the latter
two play a pivotal role in the development of cardiac ar-
rhythmias. The early identification of these alterations and
the knowledge of the pathophysiological mechanisms are
very useful for the management of these patients.
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Introduction
Heart failure is a major cause of cardiovascular mortality
and morbidity, resulting in more than one million hospi-
talizations per year in the USA, and it is the most common
hospital discharge diagnosis among subjects older than
65 years [1].
Subjects with congestive heart failure (CHF) usually
show acid–base and electrolyte disorders, due both to the
activation of several neurohumoral mechanisms and to
drugs used in this condition, such as diuretics [2]. These
abnormalities reflect the severity of CHF and contribute to
the functional impairment and to the poor long-term
prognosis [3].
The common electrolyte abnormalities are hypona-
tremia, hypokalemia, and hypomagnesemia. The acid–base
disturbances generally observed are metabolic alkalosis
pure or combined with respiratory alkalosis [4]. Several
mechanisms interact to produce these alterations. The de-
crease in cardiac output leads directly to a reduction in
renal blood flow, with impairment of renal excretion of
water and electrolytes, and it causes the activation of
several neurohormonal responses which affect both car-
diovascular homeostasis and electrolyte balance. The
therapy of CHF subjects includes the discovery and man-
agement of these electrolyte abnormalities that have a role
in the development of ventricular arrhythmias [5].
Hyponatremia
Hyponatremia is the most common electrolyte abnormality
observed in hospitalized subjects; it is defined as a serum
sodium concentration lower than 136 mmol/L [6]. Mild-to-
moderate hyponatremia is generally present in 10 % of HF
subjects [7]; however, this frequency seems to be higher in
different reports. For example, in the OPTIME-CHF trial,
27 % of subjects show serum sodium concentrations
ranging between 132 and 135 mEq/L [8], while in the
ESCAPE trial, 18 % of the subjects had persistent hy-
ponatremia throughout their hospitalization, defined as
serum sodium below 134 mEq/L [3].
Maintenance of total body salt and fluid within normal
range is under the control of the atrial-renal reflexes, the
RAAS, and the sympathetic nervous system (SNS) [9].
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In a normal heart, any increase in atrial pressure sup-
presses the release of the antidiuretic hormone, decreases
the tone of the SNS in the kidneys, and enhances the re-
lease of the atrial natriuretic peptide [10]. The latter pro-
motes sodium and water excretion at the distal nephron,
improves GFR, causes vasodilatation, and decreases the
release of the antidiuretic hormone. In HF, these actions are
blunted, and therefore sodium and water retention occurs
despite elevated atrial pressures [11]. The decrease in
cardiac output and in effective circulating volume leads to
activation of baroreceptors, which in turn activate the SNS,
the RAAS, and the release of arginine vasopressin. The
final effect is an enhanced retention of sodium and water
[12, 13] (Fig. 1).
The SNS activation helps to maintain circulatory
homeostasis and perfusion to vital organs by increasing
inotropy and chronotropy of the failing myocardium and by
modulating vascular reaction. In the long term, these
mechanisms as well as the RAAS activation are maladap-
tive and responsible for disease progression [14–16].
Furthermore, it is well known that heart and kidneys are
closely interrelated and that disorder of either of the two
organs may induce dysfunction in the other organ in a
spiral fashion leading to cardiorenal syndrome (CRS).
These two organs act in tandem to regulate blood pressure,
vascular tone, diuresis, natriuresis, intravascular volume
homeostasis, and peripheral tissue perfusion. Changes in
the RAAS, SNS, and inflammation are the cardiorenal
connectors to develop CRS [17].
As cardiac output drops, renal blood flow and GFR
follow suit, impairing the kidney’s ability to excrete dilute
urine. Dilutional impairment occurs due to disturbance of
one or more of the following mechanisms: GFR, separation
of salt and water at the thick limb of Henle’s loop, and
ADH action in the collecting duct. The volume of tubule
fluid that is delivered to the distal nephron determines in
large measure the volume of dilute urine that can be ex-
creted. Thus, if glomerular filtration is decreased or prox-
imal tubule reabsorption is greatly enhanced, the resulting







DISTAL SODIUM AND WATER DELIVERY








IMPAIRED ESCAPE FROM ACTION OF 
ALDOSTERONE AND RESISTANCE TO 
NATRIURETIC PEPTIDES
Fig. 1 Hyponatremia in heart failure. VEC extracellular fluid volume, SNS sympathetic nervous system, AVP arginine vasopressin, GFR
glomerular filtration rate
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tubule itself limits the rate of renal water excretion [18,
19].
Angiotensin II promotes the retention of sodium and
water by the stimulation of the release of aldosterone, in-
creasing the efferent arteriolar tone, hence promoting
sodium and water absorption by the resulting rise in the
filtration fraction, as well as by a direct effect on proximal
tubule [20], by stimulating the thirst center, and by causing
the release of arginine vasopressin [7].
Both adrenergic stimulation and angiotensin II activate
receptors on the proximal tubule epithelium, leading to
increased sodium reabsorption and decreased sodium and
water delivery to the renal collecting duct, thus exacer-
bating the sodium retaining effect of aldosterone and re-
ducing the diuretic effects of natriuretic peptides [12].
Furthermore, angiotensin II activates NADPH oxidase,
which results in the formation of reactive oxygen species.
The increased oxidative stress enhances negative inotropic
effects and induces cardiac remodeling [21]. Therefore, a
vicious cycle sets in promoting structural and functional
damage to both kidneys and heart. Aldosterone, in turn,
causes continuous renal sodium reabsorption and increases
the myocardial fibrosis of the failing heart [22].
Hyponatremic subjects with advanced HF often have
inappropriately elevated plasma AVP levels that in turn,
lead to enhanced renal water retention by increasing the
number of aquaporin water channels in the collecting duct
of the kidney [23].
The actions of AVP are mediated by three AVP receptor
subtypes (V1aR, V1bR, and V2R). The V1aR is located in
vascular smooth muscle cells and cardiomyocytes mediat-
ing vasoconstriction and hypertrophy, platelets aggrega-
tion, and glycogen metabolism in hepatocytes. The V1bR
located in the anterior pituitary play a crucial role in
regulating hypothalamic–pituitary–adrenal axis activity by
stimulating the release of corticotrophin and ACTH. The
V2R located in the collecting tubules of the kidney are
notable in the pathophysiology of HF and mediate the
antidiuretic effect of AVP. Binding of AVP to V2R acti-
vates the adenylate cyclase signaling pathway, leading to
phosphorylation of the preformed water channel aquaporin-
2 and their subsequent insertion into the apical membranes
of the collecting ducts. Furthermore, the urinary excretion
of aquaporin-2 is increased in heart failure subjects with
elevated AVP [24]. Notably, the elevated plasma AVP
levels are not adequately reduced even with acute water
loading in hyponatremic HF subjects [23].
The AVP cannot be reliably investigated by the current
laboratory methods; however, copeptin, the C-terminal
segment of the AVP precursor peptide, is secreted in an
equimolar ratio to AVP and is a sensitive and stable sur-
rogate marker for its release. Copeptin is also a promising
indicator in the differential diagnosis of hyponatremia [25].
Hyponatremia may be a marker of neurohormonal ac-
tivation that reflects the severity of heart failure [26], but it
may also result from the HF therapy [7, 27].
Diuretics are one of the most common causes of drugs
induced hyponatremia; Although thiazide diuretics are
most often implicated [28], also non-thiazide agents, such
as furosemide, spironolactone, and indapamide, have been
associated with hyponatremia [29].
It should also be mentioned that the hydrochlorothiazide
and amiloride combination increases the risk of hypona-
tremia. This increment is probably due to the direct effect
of amiloride on the collecting tubule increasing sodium
loss. Moreover, amiloride spares potassium and, therefore,
worsens thiazide-induced hyponatremia as a consequence
of potassium retention by exchanging it for sodium in the
distal tubule [30].
Several clinical studies have shown that hyponatremia is
associated with adverse prognosis and reduced survival in
HF [31]. Serum sodium concentration on admission or dis-
charge is a predictor of in-hospital short-term and long-term
mortality in subjects hospitalized for HF [32, 33]. Moreover,
hyponatremia is associated with an increased rate of re-
hospitalization and major complications [32], as well as a
longer hospital stay in hospitalized HF subjects [34, 35]. In a
study of 355 subjects admitted for HF, a serum sodium
concentration\130 mEq/L was associated with a higher in-
hospital death rate [36]. In the OPTIME-CHF study, sub-
jects with serum sodium\135 mEq/L had longer lengths of
hospital stay and a doubling of in-hospital as well as 60-day
mortality [8]. Finally, serum sodium levels also predict
mortality in outpatients with chronic heart failure [33, 37].
The treatment of significant hyponatremia in heart fail-
ure is not easy. The conventional treatments such as fluid
restriction, infusion of hypertonic saline, and conventional
diuretic therapies are not usually effective. Vasopressin
receptor antagonists have been shown to enhance aquaresis
and correct hyponatremia. However, long-term beneficial
effects of such treatments in chronic heart failure have not
been validated [38].
Hypokalemia
Hypokalemia is commonly observed in CHF subjects, and
it is a strong independent predictor of mortality [39].
Hypokalemia has not been well defined in HF, and even
in the literature, its range varies from 3.5 to 4.0 mEq/L
(mmol/L) [40]. Hypokalemia is generally more evident in
subjects with advanced CHF receiving pronounced diuretic
therapy and with the greatest activation of the renin–an-
giotensin system [41].
Low levels of serum K? may be a marker of increased
neurohormonal activity and disease progression [42];
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furthermore, serum K? is negatively correlated with plas-
ma renin activity and plasma noradrenaline [43].
Catecholamines cause hypokalemia and increase the
arrhythmic risk; adrenaline, in fact, stimulates the sodium–
potassium-ATPase pump via b2-receptors and shifts
potassium intracellularly. It seems likely that the observed
mortality benefit with beta-blockade in HF is partly
ascribable to the prevention of hypokalemic arrhythmias
[44].
It is known that potassium depletion is a risk factor for
increased frequency of ventricular arrhythmias; moreover,
hypokalemia can potentiate the arrhythmias associated
with CHF therapy (e.g., digitalis) and diminish the efficacy
of anti-arrhythmic drugs by altering the electrophysiologic
properties of the myocardium and negating some of the
antiarrhythmic activity of these agents. The frequency of
ventricular ectopic beats and the frequency of sudden death
correlate with both serum and whole body levels of
potassium [45].
A total of 50 % of deaths from HF are sudden, pre-
sumably due to arrhythmias. In victims of sudden cardiac
death (SCD), the level of myocardial K? is often lower
than in controls, and survivors may show hypokalemia
apparently caused by a shift of potassium from the in-
travascular compartment [46]. It is unclear whether hy-
pokalemia precedes and causes the episode or occurs as a
result of resuscitation; however, it was found a correlation
between the decreased serum K? (\4.4 mEq/L) and SCD
[47].
In HF, all-cause and cardiac mortality rates are higher in
subjects taking non-K?-sparing diuretics; furthermore, the
incidence of arrhythmic death is significantly and inde-
pendently correlated with the use of non-K?-sparing di-
uretics [48].
In HF subjects, there is evidence that the serum potas-
sium level should be maintained above 4.5 mEq/L to
minimize the risk of SCD [40, 47, 49], while Leier et al.
[50] advise maintaining the level in the range of 4.5 to
5.0 mEq/L. A mild hypokalemia may be corrected by the
use of aldosterone receptor antagonists such as spirono-
lactone or eplerenone, while a more severe hypokalemia
should preferably be corrected using K? supplement [40].
However, potassium replacement should be routinely
considered in patients with CHF, even if the initial potas-
sium determination appears to be normal [51].
Potassium depletion causes diastolic dysfunction [52],
while high potassium protects against hypertensive en-
dothelial dysfunction [53, 54].
Potassium mediates vasodilation via strong inwardly
rectifying potassium channels and the sodium–potassium-
ATPase pump of vascular smooth muscle cells, and this
may be useful when NO bioavailability is low; potassium
also reduces angiotensin II-induced vasoconstriction [55].
In vitro, high extracellular potassium concentration im-
pairs platelet aggregation; moreover, in animal models,
increasing plasma potassium reduces the rate of thrombosis
on endothelial lesions. Potassium ameliorates oxidative
stress by reducing free-radical formation, diminishing
vascular smooth muscle cell proliferation, and reducing
monocyte adherence to vessels [56]. Furthermore, potas-
sium appears to have an antihypertensive effect mediated
by increased natriuresis, vasodilation, heightened barore-
flex sensitivity, and reduced cardiac sensitivity to
catecholamines and angiotensin II [57]. Potassium also
seems to retard the progression of atherosclerosis [56]
(Fig. 2).
While diuretics and adrenergic stimulation may cause
hypokalemia, neurohormonal blockade using ACE in-
hibitors, angiotensin receptor blockers, beta-blockers, and
aldosterone antagonists may cause hyperkalemia and so the
serum K? level should be frequently checked in these
subjects [58].
As result of different studies, the myocardiocytes would
present mechanisms of adaptation to chronic hypo- or hy-
per-kalemia. Studies in animal models showed that cardiac
muscle was protected against loss of potassium during
chronic potassium depletion by an adaptive increase in the
density of sodium pump. An increase in the activity and
quantity of (Na?–K?) ATPase in the myocardial tissue
would protect it against K? loss. It is not yet known
whether these results can be extrapolated to human beings
[59–61].
Bartter’s syndrome offers a opportunity to study clinical
effects of chronic electrolyte disturbances. Although ex-
tracellular concentrations of potassium were usually very
low in these subjects, the electrocardiographic changes
were slight and arrhythmias were not common. This pattern
may reflect an adaptation of the myocardium to hy-
pokalemia [62].
In a study, intracellular K? concentration and ATPase
activity of myocardiocytes were measured in early stage of
burn injury. The latter accelerates K? efflux current, but
inhibits K? influx current; the reduction in Na?–K?-
ATPase activity may be one reason for decrease in intra-
cellular K? concentration after injury [63].
Hypomagnesemia
Magnesium plays a role in many enzymatic processes, and
it is an important component in the mitochondrial structure
and function; it modulates cellular potassium permeability
and affects calcium uptake and its distribution [64, 65].
Hypomagnesemia (serum magnesium \1.5 mg/dL) is not
infrequently observed in CHF subjects, but its patho-
physiology remains less studied when compared to other
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electrolyte alterations. However, there is evidence that
early detection and correction of magnesium abnormalities
could remedy potentially dangerous arrhythmogenic ef-
fects. There is also confirmation that the effective correc-
tion of magnesium disturbances is favorable in CHF
subjects [66].
Hypomagnesemia occurs either as an isolated distur-
bance or in association with other acid–base and electrolyte
abnormalities; several interrelated mechanisms are impli-
cated in its pathogenesis [67]. As magnesium and potas-
sium are mainly intracellular ions, measurements in serum
or plasma are of limited value to assess magnesium status.
There was no correlation between the intracellular elec-
trolyte content and the electrolyte levels in plasma, either
for mononuclear cells or erythrocytes or for myocardial
and skeletal muscle [68].
In the setting of CHF, magnesium depletion stems from
reduced dietary intake, altered distribution of the ion, and
renal losses. It should also be considered that edematous
states, involving the intestinal mucosa, might interfere with
the absorption of microelements, such as magnesium.
Respiratory alkalosis may produce a decrease in serum
magnesium due to a shift of magnesium inside the intra-
cellular compartment. Furthermore, it is well documented
that an excessive catecholamine release in decompensated
CHF can significantly influence the trans-cellular magne-
sium shift [69].
Diuretics (loop-acting diuretics in particular) produce
most of renal magnesium loss, especially in the volume-
expanded setting of CHF and in associated hyperaldos-
teronism [69].
It has been demonstrated that potassium depletion in-
hibits the reabsorption of magnesium in the distal convo-
luted tubule, thus leading to hypermagnesiuria and
hypomagnesemia [70]. However, it is well documented
that primary disturbances of magnesium balance, par-
ticularly magnesium deficit, produce secondary cellular
potassium depletion [71] (Fig. 3).
Furthermore, it has been hypothesized that the detection
of electrolyte disorders, such as hypokalemia, hypona-
tremia, hypophosphatemia, hypocalcemia, and especially
refractory potassium depletion in CHF subjects, should alert
to the possibility of coexisting magnesium depletion [72].
The prevalence of hypomagnesemia in CHF subjects
ranges from 7 % of well-compensated ambulatory subjects
to 52 % in more advanced CHF subjects who are treated
aggressively with diuretics [73].
In animal models, magnesium deficiency leads to the
development of mitochondrial alterations with calcium ac-
cumulation, cell death, and multifocal myocardial necrosis
[74].
Hypomagnesemia seems to have vasoconstrictor prop-
erties, secondary to the inhibition of prostaglandin-induced
relaxation and to the enhancement of the activity of the
vasoconstrictor neurohormones through alterations in cal-
cium uptake. Furthermore, hypomagnesemia can poten-
tially induce hypercoagulability, via enhanced adenosine
diphosphate-induced platelet aggregation [75].
The worsening of CHF secondary to very severe hypo-
magnesemia has been described, and in some cases, mag-










Fig. 2 Hypokalemia in heart
failure. RAAS renin–
angiotensin–aldosterone system
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Moreover, the mortality increase in CHF subjects with
hypomagnesemia was believed to be related to the devel-
opment of ventricular arrhythmias rather than clinical and
hemodynamic deterioration. Elevated levels of magnesium
decrease the sensitivity of myocardium to the antiarrhyth-
mic action of cardiac glycosides. Digoxin directly limits
the renal tubular reabsorption of magnesium, therefore
increasing magnesium excretion; a low magnesium con-
centration increases the action of cardiac glycoside. The
antiarrhythmic action of magnesium is mediated by a re-
duced sensitivity to electrophysiologic changes induced by
Ca2?. The prognostic significance of serum magnesium
concentration in CHF subjects is currently under investi-
gation, although in a retrospective study of subjects with
moderate-to-severe CHF, an inverse correlation was noted
between mortality and plasma magnesium [77].
Hypocalcemia and hypophosphatemia
Hypocalcemia (total serum calcium concentration
\8.6 mg/dL or ionized calcium concentration\1.1 mmol/
L) and hypophosphatemia (serum phosphorus concentration
\2.7 mg/dL) are less investigated in HF subjects even
though not of minor importance. Despite the pivotal role of
calcium ions in contraction of cardiac muscle [78], few
cases of hypocalcemia in CHF have been reported and
these are often in association with hypomagnesemia [4].
The clinical setting of hypocalcemia includes hy-
poparathyroidism, end-stage kidney disease, and respira-
tory alkalosis [79]; in addition, loop diuretics block the
reabsorption of calcium in the loop of Henle and may play
a role in the pathogenesis of hypocalcemia [80].
It was shown that the correction of calcium disorder
could improve CHF [81].
In CHF subjects, hypophosphatemia is generally due to
phosphate loss ascribed to respiratory alkalosis, to hypo-
magnesemia, and to phosphaturic effects of diuretics [82].
Phosphorus depletion has been associated with re-
versible cardiomyopathy [83].
Some research showed an evident association of in-
creased levels of inorganic phosphate with CHF hospital-
ization even if the nature of this relationships is not clear
[84]; an explanation might be found in features of a my-
ocardiocyte metabolism. It has recently been supposed that
inorganic phosphate is both the primary feedback signal for
stimulating oxidative phosphorylation and also the most
significant product of ATP hydrolysis in limiting the heart
capacity to hydrolyze ATP [85].
It is known that inorganic phosphate plays a role in the
down-regulation of myocardial contractile force at the














Fig. 3 Pathogenesis and effects
of hypomagnesemia in CHF.
RAAS renin–angiotensin–
aldosterone system
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correlation between inorganic phosphates and systolic
blood pressure [87].
Acid–base abnormalities in CHF
In CHF, various acid–base disorders can be discovered due
to the renal loss of hydrogen ions and hydrogen ion move-
ments into cells, the reduction in the effective circulating
volume, hypoxemia, and renal failure. This justifies the oc-
currence of metabolic alkalosis, metabolic acidosis, respi-
ratory alkalosis, as well as respiratory acidosis alone or in
combination. Several studies have systematically evaluated
the prevalence of acid–base disturbances in CHF [88–90].
About 37 % of CHF subjects show at least one acid–base
abnormality, most commonly metabolic alkalosis, alone or
associated with respiratory alkalosis. Alkalemia is more
common in subjects with more advanced CHF (36 % in
subjects with class IV compared with 11 % of those with
class III) [4]. Other studies confirm the trend toward alka-
lemia of mixed metabolic and respiratory origin in un-
selected advanced CHF subjects [88, 90]. In addition,
diuretic therapy increases the prevalence of metabolic alka-
losis, although the subjects who improve the circulatory
status with diuretic therapy may improve their alkalosis [91].
In normal conditions, the kidney preserves normal acid–
base balance by bicarbonate reabsorption, principally in the
proximal tubule, and bicarbonate generation, pre-
dominantly in the distal tubule. Bicarbonate reabsorption is
influenced by an effective circulating volume, glomerular
filtration rate, and serum potassium level, whereas bicar-
bonate generation is affected by distal sodium delivery and
reabsorption, aldosterone level, arterial pH, and pCO2 [92].
In states of volume depletion, the increase in renal
avidity for sodium reabsorption results in an acceleration of
the sodium–potassium exchange mechanisms, leading to
the development of negative potassium balance and
favouring the maintenance of metabolic alkalosis [93]. In
this case, there is a reduction in bicarbonate back leak from
the renal interstitium to the tubular lumen and a consequent
increase in the net tubular bicarbonate reabsorption [94].
The renal loss of hydrogen ions in heart failure is related
to mineralcorticoid excess and to the increased production
of angiotensin II. Mineralcorticoids stimulate the apical
sodium channel and basolateral Na?–K? ATPase and in-
creased sodium reabsorption promoting secretion through
the apical potassium channel. About two-thirds of filtered
sodium is reabsorbed with Cl- or in exchange for H? in the
proximal tubule. Proximal tubule reabsorption is increased
by angiotensin II through the constriction of the efferent
glomerular arteriole and through the increase in filtration
fraction and in the number of Na?–H? exchangers. The
final effect is to retain sodium, to deplete potassium, and to
produce extracellular alkalosis; furthermore, coexistent


















Fig. 4 Metabolic alkalosis in
CHF. CHF congestive heart
failure, VEC extracellular fluid
volume
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potassium depletion increases plasma renin activity and
angiotensin II production [95].
Diuretics employed in heart failure are frequently re-
sponsible for metabolic alkalosis due to several possible
mechanisms. Diuretics cause an increase in sodium deliv-
ery to the distal nephron and accelerate potassium and
proton secretion; furthermore, volume contraction stimu-
lates renin and aldosterone secretion. Potassium depletion
with an aldosterone excess is always accompanied by
metabolic alkalosis. Hypokalemia promotes alkalosis
principally through two mechanisms: first, hydrogen shifts
from the extracellular to the intracellular compartments in
exchange for potassium, thereby contributing to the alka-
lemia, and second, hypokalemia produces a stimulation of
bicarbonate reabsorption in the proximal tubule and in-
creases the acid excretion [96] (Fig. 4).
Alkalosis seems to be an adverse prognostic factor; in a
recent study, the in-hospital mortality rate was higher in the
alkalosis group (14.1 %) than in the normal (4.5 %) and
acidosis groups (9.3 %) of HF subjects [97].
The treatment of metabolic alkalosis is based on chlo-
ride and potassium repletion, enhancement of renal bicar-
bonate excretion (such as acetazolamide), or, if
accompanied by kidney failure, low-bicarbonate dialysis.
In CHF, an appropriate management of circulatory failure
and the use of aldosterone antagonists in the diuretic
regimen are useful for its treatment. In end-stage heart
failure, a progressive reduction in plasma renal flow and in
GFR leads to renal failure with the reduced capacity of the
kidneys to excrete net acid, which can then induce a
metabolic acidosis [98].
Light and George [99] evaluated the changes in pul-
monary function in 28 subjects hospitalized for CHF, and
they showed that initially, subjects had both obstructive
and restrictive ventilatory dysfunction. In another study,
Niset et al. evaluated the reversibility of the lung dys-
function in 47 patients with severe CHF before and 1 year
after heart transplantation. They affirmed that the restric-
tive ventilatory defect induced by chronic HF was re-
versible, whereas the exception of the reduction in
diffusion lung capacity for carbon monoxide was not im-
proved, which probably reflected irreversible changes in
the lung vasculature [100].
Subjects with heart failure and with pulmonary edema
can develop respiratory alkalosis in the presence of sus-
tained alveolar hyperventilation that causes hypocapnia. In
fact, the stagnation of liquid in the perivascular and peri-
bronchial connective and in the interstitial spaces of the
alveolar septa stimulates receptors J and produces a reflex
hyperventilation [101].
Effects of acid–base disorders on cardiovascular func-
tion are well known. Depression of the cardiac function is
observed mainly with respiratory and metabolic acidosis,
whereas respiratory alkalosis, mediated by a SNS, inter-
feres on blood pressure and cardiac arrhythmias. The latter
are frequently found in metabolic alkalosis associated with
hypokalemia [102].
In end-stage heart failure, the most common complica-
tion is the pulmonary edema. Positive airway pressure
(PAP) therapy represents a potentially beneficial non-phar-
macological approach in this clinical condition [103, 104].
PAP diminishes systemic venous return and right ven-
tricular (RV) preload by increasing intrathoracic pressure;
it also alters pulmonary total vascular resistance that is the
major determinant of RV afterload [105]. In ADHF, PAP
therapy increases oxygenation through the recruitment of
collapsed alveoli, induces fluid shifts back from alveoli and
interstitial space to the pulmonary circulation, reduces
respiratory muscle load and the work of breathing, and
stabilizes hemodynamics [105].
Conclusions
CHF subjects develop multiple acid–base and electrolyte
abnormalities due to several pathophysiological mechan-
isms. Their incidence is often correlated with the severity
of cardiac dysfunction; furthermore, these imbalances are
associated with a poor prognosis. Many of these metabolic
derangements are drug-induced; therefore, these subjects
need close monitoring. When treating CHF, one must
consider how to prevent and to correct electrolyte
imbalances.
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